Top in cardiology: Benefits of empagliflozin, walnut consumption
Click Here to Manage Email Alerts
Recent data from the EMPEROR-Preserved trial revealed that the SGLT2 inhibitor empagliflozin reduced the risk for serious hospitalizations in patients with heart failure with preserved ejection fraction.
A report on the trial data was the top story in cardiology last week.
Another top story revealed that daily walnut consumption “is a simple way to promote cardiovascular health,” according to Emilio Ros, MD, PhD.
Read these and more top stories in cardiology below:
EMPEROR-Preserved: Empagliflozin reduces risk for serious hospitalizations in HFpEF
In patients with heart failure with preserved ejection fraction, empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) reduced the risk for serious hospitalizations compared with placebo, according to new data from the EMPEROR-Preserved trial. Read more.
Daily walnut consumption lowers total cholesterol, LDL at 2 years
Healthy older adults who consumed walnuts daily for 2 years experienced reductions in total cholesterol and LDL, as well as small and total LDL particles, according to results of the WAHA trial. Read more.
Healthy sleep patterns may lower arrhythmia risk
Healthy sleep patterns may be associated with reduced risk for atrial fibrillation/atrial flutter and bradyarrhythmia, according to research published in the Journal of the American College of Cardiology. Read more.
Elevated stress hormones confer increased risk for hypertension
Elevated levels of stress hormones such as norepinephrine, epinephrine, dopamine and cortisol were associated with increased risk for hypertension, and high levels of cortisol was also linked to cardiovascular events, researchers reported. Read more.
GALACTIC-HF: Omecamtiv mecarbil effective in Black patients with HF
Omecamtiv mecarbil (Cytokinetics) was safe and effective compared with placebo in Black patients with heart failure with reduced ejection fraction, according to new data from GALACTIC-HF presented at the Heart Failure Society of America Annual Scientific Meeting. Read more.